177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 152 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Exercising Safely During Breast Cancer Treatment: What to Know October 27, 2022 FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive Breast... July 2, 2020 Diagnosed Alone October 6, 2020 Online Dating During COVID-19 and Cancer: What to Know February 11, 2021 Load more HOT NEWS Talking About Your Sexual Orientation and Gender Identity With Your Cancer... Studying Genes and Proteins Together Sheds New Light on Colon Cancer The Potential of AI to Improve Cancer Care is Only Going... Veteran Avoided The Barber For 6 Years After He Left The...
